Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neximmune Inc.
Headquarters: Gaithersburg, MD, United States of America
Website: http://www.neximmune.com
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Craig R. Jalbert
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 0
Exchange/Ticker 1: NASDAQ:NEXI
Exchange/Ticker 2: N/A
Latest Market Cap: $100
BioCentury | Aug 14, 2024
Finance
Seeding the next wave of myeloma drug development
How the Myeloma Investment Fund approaches venture philanthropy and views the future of the myeloma treatment landscape
BioCentury | Oct 27, 2022
Discovery & Translation
Reducing off-target base editing; plus a CAR T-enhancing switch and more
BioCentury’s roundup of translational news
BioCentury | Apr 23, 2021
Management Tracks
Genfit unveils a new CFO; plus Evotec, Autolus, Celyad, Lumos, Dewpoint and more
Metabolic and liver diseases company Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) hired Thomas Baetz as CFO. Baetz was director of healthcare at Dragon Financial Partners. Wolfgang Plischke will step down
BioCentury | Feb 13, 2021
Deals
Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare
Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday after the companies priced IPOs on NASDAQ Thursday night. Hearing and balance therapy
BioCentury | Jan 20, 2021
Finance
IPO queue bulges further as Adagene, NexImmune are among latest to file
After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The
BioCentury | Jan 20, 2021
Management Tracks
Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune
Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge
BioCentury | Jan 16, 2021
Management Tracks
FDA’s Schiller joins Aetion; plus Novavax, NHC, NextCure, Ziopharm, ONK
Lowell Schiller left FDA to join Aetion Inc. as chief legal and regulatory officer. For nearly the past two years, Schiller was principal associate commissioner for policy, serving briefly
BioCentury | Feb 17, 2017
Finance
NexImmune’s next act
How differing opinions on pipeline strategy led to NexImmune buyout
Items per page:
1 - 10 of 17